Halozyme Therapeutics Stock: 6 Straight Green Days, Up 14%
Halozyme Therapeutics (HALO) stock has risen for 6 consecutive trading days, gaining 13.9% over that stretch. That added about $1.8 billion to the company’s market value, which now stands at about $14.6 billion. The stock closed at $124.83 on Wednesday, October 21, its highest close of the past year.
How The Streak Stacks Up Against The S&P 500
Returns for HALO and the S&P 500 over the streak and the periods around it, all ending Wednesday, October 21 and including dividends:
| Return Period | HALO | S&P 500 |
|---|---|---|
| 1 Day | 0.4% | 0.6% |
| 6 Days (Current Streak) | 13.9% | -0.6% |
| 1 Month (21 Trading Days) | 8.4% | 0.0% |
| 3 Months (63 Trading Days) | 54.4% | 5.0% |
| Year To Date | 85.5% | 14.4% |
| 1 Year (252 Trading Days) | 87.8% | 16.5% |
Is This Move About Halozyme Therapeutics Or The Market?
Over the same 6 trading days, the S&P 500 returned -0.6% including dividends, so the run is mostly Halozyme Therapeutics’ own story rather than the market’s. Over the past three months the stock is up 54.4%, a window that includes the streak; over the other 57 sessions of that window it was up 35.6%.
Do The Fundamentals Support The Run?
On the fundamentals, revenue grew 41.2% over the last twelve months, against a median of 8.1% for S&P 500 Health Care stocks; and its operating margin is 55.9%, versus a median of 17.6%. At least one of the last four quarters was a loss, so a price-to-earnings multiple would not be a meaningful yardstick here. The business gives the rally real support, with revenue growth above the median and margins above the median.
A climb like this is worth respecting, and worth testing. Our Guidance Momentum screen tracks the stocks whose companies just raised their own forward numbers.
For anyone who would rather back the theme than one company, a biotech ETF like XBI holds the whole group, not just this stock. It is still a concentrated bet on one theme, which is the gap the portfolio below is built to close.
Streaks End. Discipline Compounds
A run like this is genuinely useful information: something about this business has the market’s full attention. But streaks are where discipline gets tested, because the urge to chase strength is strongest right before it pauses.
The Trefis High Quality (HQ) Portfolio channels that urge into a system: roughly 30 businesses selected for consistent cash generation, strong margins, and resilient balance sheets, sized and rebalanced with rules rather than excitement. It has a track record of outpacing a benchmark that combines the S&P 500, the S&P MidCap 400, and the Russell 2000. Enjoy the streak; own the process.